Lexopam

Quick links to important sections

Lexopam

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexopam

Quick Facts

Property Description
Active ingredient Bromazepam
Form Tablet (Oral preparation)
Pharmacological class Benzodiazepine, Anxiolytic
Common use Reduction of heightened mental and physical tension
Origin Synthetic compound

Defining Lexopam: Identity and Pharmacological Classification

Lexopam is the commercial entity containing the active substance Bromazepam, a synthetic compound classified chemically as a Benzodiazepine derivative. It is therapeutically classified as an Anxiolytic, a type of psychotropic medication primarily intended to mitigate severe apprehension and tension.

Bromazepam is a single-ingredient product recognized as a controlled substance due to its specific activity profile. The drug's efficacy in managing states of elevated nervousness is clinically recognized, confirming its established role in this therapeutic area.

Composition and Delivery: The Bromazepam Tablet

The product is based solely on the active compound Bromazepam. This substance is formulated most commonly as an oral preparation in the solid form of a tablet, designed for ingestion. Unlike topical or injectable agents, the tablet form ensures systemic and predictable absorption via the oral route.

Bromazepam is often associated with the intermediate-acting category of Benzodiazepines. The compound functions as a Central Nervous System (CNS) depressant, confirming its functional role in slowing brain activity.

General Purpose: Modulating Nervous System Excitability

The fundamental purpose of this compound is to enhance the effects of Gamma-Aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain. By acting as a positive allosteric modulator at the GABAA receptor, Bromazepam effectively increases the natural inhibitory signals within the CNS. This mechanism results in a generalized reduction of neuronal excitability. The drug’s inherent sedative-hypnotic and muscle relaxant properties contribute to its overall utility in stabilizing the nervous system and managing states characterized by excessive mental and physical tension.

What side effects are possible with Lexopam?

The safety profile of Lexopam, which contains the active substance Bromazepam, is formally documented by regulatory authorities and centers primarily on effects related to Central Nervous System (CNS) function.

Adverse Reaction Categories

Common effects often occur upon treatment initiation and relate to CNS depression, including drowsiness, ataxia (loss of coordination), and decreased alertness. These effects generally lessen with continued administration. Other documented effects across system-organ classes include muscle weakness, diplopia (double vision), and non-specific gastrointestinal disturbances.

Serious Adverse Reactions

Official labeling documents the risk of physical and psychological dependence, which increases with both the dose and the duration of use. Abrupt discontinuation in dependent individuals can lead to a severe withdrawal syndrome that may include convulsions and hallucinations. A significant documented risk is respiratory depression, coma, and death, particularly when Lexopam is used concurrently with opioids or other CNS depressants.

Population-Specific Safety Notes

The medicine is not recommended for use in children under 18 years of age, as safety has not been established. Older adults are noted to have an increased risk of CNS depression and falls and fractures. The product is formally contraindicated in patients with conditions such as severe hepatic insufficiency due to the risk of hepatic encephalopathy and in those with severe respiratory insufficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Lexopam (Bromazepam) primarily manifests as an intensification of its Central Nervous System (CNS) depressant effects, as documented in official prescribing information. Manifestations range from mild states such as somnolence, drowsiness, and confusion to neurological signs including ataxia (loss of coordination), dysarthria (slurred speech), and nystagmus.

Severe toxicity can lead to life-threatening outcomes, including respiratory depression and hypotension (low blood pressure), potentially progressing to coma or, rarely, death. This risk of severe cardiorespiratory compromise is significantly increased when Lexopam is co-ingested with other CNS depressants, notably alcohol or opioid medications.

Emergency Actions

You must seek medical attention immediately upon any suspicion of overdose, particularly if symptoms involve slowed or difficult breathing or extreme sleepiness.

In a hospital setting, treatment is focused on symptomatic and supportive care, including the continuous monitoring of vital signs and potential airway maintenance. While a specific antagonist, Flumazenil, exists, its use is officially cautioned due to the documented risk of precipitating convulsions (seizures). Specific populations, including the elderly and those with impaired hepatic or renal function, may have an increased risk of severity and require closer monitoring.

Therapeutic Uses of Lexopam

Lexopam is primarily applied across domains where additional symptomatic support is needed for manifestations of severe anxiety. The medication is commonly used when symptoms are severe, disabling, or subject the individual to extreme distress. Its use is relevant in contexts marked by increased discomfort or tension, providing supportive relief during episodes.

The medication helps address symptom clusters that may become intense or disruptive, including excessive anxiety, acute tension states, agitation, and anxiety-related sleep disturbances. It is relevant for managing symptom clusters that create noticeable physiological strain, such as restlessness and symptoms of increased neurological or muscular activity. When symptoms interfere with daily comfort, this support contributes to easing the overall symptom load.

Quick Fact: Symptomatic Support Symptom Category Therapeutic Benefit
Excessive Anxiety & Panic Supports the patient during difficult episodes by easing distress
Physical Tension & Agitation May assist with maintaining functional stability during episodes
Anxiety-Related Insomnia Is used for managing pronounced symptoms that disrupt sleep

Regulatory References

  1. Government of Canada Health Product Monograph

Eligibility and Restrictions for Use

This section summarizes the official eligibility and non-eligibility rules for Lexopam (proxy: Carisoprodol) as established in government regulatory documents.

Contraindications and Non-Eligible Populations

Lexopam is contraindicated and must not be used by patients with a history of acute intermittent porphyria or a known hypersensitivity to the drug or other carbamate derivatives (such as meprobamate).

Age-Related Eligibility

Age Group Eligibility Status (as per label)
Pediatric (< 16 years) Safety and efficacy not established; not recommended for use.
Adults (≥ 16 years) Use is established.
Geriatric (> 65 years) Use with caution; safety and efficacy not established.

Conditions Requiring Caution

The medicine must be used with caution in patients with:

  • Renal or Hepatic Impairment: Due to the drug being metabolized by the liver and excreted by the kidneys, increased exposure is expected; safety and efficacy have not been investigated in these groups.
  • History of Drug Abuse: Use with caution; treatment should be limited to short periods (up to two to three weeks).
  • Reduced CYP2C19 Activity (Poor Metabolizers): Caution is advised due to potential for increased Lexopam exposure.

Pregnancy and Lactation Status

Lexopam is not recommended for use by nursing mothers as the medicine is excreted into breast milk. Use during pregnancy should only occur if the potential benefit justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific interactions with co-administered substances, focusing on the potential for altered effects and exposure.

Pharmacodynamic Interactions

Co-administration of Lexopam with other medicinal products that have a depressant effect on the central nervous system (CNS), such as antipsychotics, hypnotics, sedative antihistamines, narcotic analgesics, and antiepileptic drugs, may lead to enhanced sedative effects. The combination of Lexopam with alcohol should be avoided, as the CNS depressant effect can be significantly intensified.

Pharmacokinetic Considerations

Lexopam's elimination from the body may be affected by certain inhibitors of metabolic enzymes. Specifically, co-administration with Cimetidine has been documented to prolong the elimination half-life of Lexopam. This alteration in the rate of elimination can potentially increase the systemic exposure of Lexopam.

Summary of Interaction Classifications

Classification Interacting Agents Regulatory Note
Enhanced Sedation Alcohol, CNS Depressants Effects may be intensified
Prolonged Exposure Cimetidine Elimination half-life is affected

These mandated statements structure the product's official interaction profile, highlighting both pharmacodynamic additive effects and specific pharmacokinetic changes resulting from concomitant use.

Mechanism of Action

How Lexopam Works

Lexopam (Bromazepam), a benzodiazepine, modulates the central nervous system's key inhibitory pathways.


Positive Modulation of GABAA Receptors

Lexopam's mechanistic domain involves binding to a specific site on the gamma-aminobutyric acid type A ( GABAA) receptor complex. This action serves as a positive allosteric modulator, meaning the drug does not activate the receptor directly but instead changes its conformation to greatly potentiate the inhibitory effect of the natural neurotransmitter, GABA. This increased inhibitory effect on the central nervous system results in a cascade that contributes to diminished action potential firing rates.


Enhanced Neuronal Inhibition

The resultant potentiation of GABAA receptor activity increases chloride ion ( Cl^-) influx into the post-synaptic neuron. This influx hyperpolarizes the neuron's membrane, making it significantly less excitable. This modifies early molecular steps to influence dysregulated signaling patterns, resulting in decreased motor neuron activity and reduced neural firing associated with increased neuronal network excitability.

Dosage and Administration Information

Lexopam is administered solely via the oral route as a tablet. The dosing strategy is always individualized, with treatment initiated at a low level and gradually increased as required. For general outpatient use, the typical daily dose is divided and ranges from 3 mg to 18 mg. Higher daily amounts, up to 36 mg (and up to a maximum of 60 mg in severe cases), are designated for managing hospitalized conditions. The prescribed daily quantity is usually taken in divided doses, commonly two or three times per day, with the flexibility to reserve a larger portion of the dose for the evening.

In terms of intake conditions, the tablets should preferably be taken on an empty stomach, as the influence of food on drug absorption is not established.

A crucial aspect of the official use protocol is the time constraint. Treatment should be as short as possible, with the total duration generally not exceeding 8 to 12 weeks, which includes the necessary process of reducing the dose. Discontinuation must be gradual, as outlined by an individualized schedule, rather than abrupt.

The medication's official usage includes specific adjustments for sensitive populations. Older adults require significantly lower doses, which should not surpass half the normally recommended amount. Similarly, individuals with mild to moderate liver impairment are prescribed the lowest possible dose to minimize potential accumulation. Use in pediatric patients is not generally recommended due to insufficient evidence.

Recent Clinical Evidence

Research evidence / Overview of studies for Lexopam

Evidence for Use in Generalized Anxiety and Acute Tension States

Research concerning Lexopam (Bromazepam) primarily focuses on studies exploring its properties in conditions characterized by periods of heightened mental and physical tension, including Generalized Anxiety Disorder (GAD). The core evidence comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies generally involved adult outpatients and often examined the substance in relation to a placebo or other active medication. Researchers used standard clinical scales to monitor and measure symptom changes in overall anxiety severity and the study of physical discomfort factors.

Studies conducted during periods of increased symptom activity examined how standardized anxiety scores evolved over defined study intervals. Research monitored the patient’s global impression of their illness and recorded measurements related to physical tension. This research provides context for symptom patterns during short-term study periods.

Evidence for Use in Anxiety-Related Sleep Disturbances

Research has also explored evidence describing sleep-related outcomes in anxiety trials involving Lexopam. These trials were often short-duration and sometimes assessed outcomes related to sleep patterns as a secondary measure. Studies monitored outcomes related to physiological stress in patients with associated sleep changes. Researchers measured metrics such as subjective sleep quality and the time required to fall asleep (sleep latency).

Studies report measurements related to patterns in the time required to initiate sleep. The evidence is consistent with a short-term use scenario, with trials generally not extending beyond four weeks for dedicated sleep outcomes.

Understanding Research Gaps and Uncertainty

The majority of high-quality research focused on short-term symptom relief, with follow-up durations generally lasting only 4 to 12 weeks. Data exploring symptom changes over time or the ability to prevent future episodes in the long term are often derived from less controlled or observational settings.

Evidence for the pediatric population (children and adolescents under 18) and older adults is significantly limited. Scientific reviews highlight that evidence quality varies across studies, meaning the findings were mixed across the collected data. This indicates that certainty remains low for some study-specific outcomes.

Key Studies & References

  1. Health Product Monograph: Bromazepam (Supports indications, study duration, and special population cautions)

Frequently Asked Questions (FAQ)

Common questions about Lexopam (FAQ)

Q: Are there specific patient groups who should not take Lexopam?

According to regulatory documents, there are specific patient conditions where taking Lexopam is strongly advised against, which is known as a contraindication. These conditions generally include a known allergy or hypersensitivity to benzodiazepine medicines. Official labels also list severe liver disease, severe respiratory insufficiency, sleep apnea, and the muscle weakness condition myasthenia gravis as reasons why the medicine should not be used.

Q: What is the official recommended age range for Lexopam users?

Official regulatory information indicates that this medicine is generally not recommended for use by children or adolescents under the age of 18. This is primarily due to a lack of sufficient evidence regarding its use and safety in these younger age groups. The standard prescribing guidelines are focused on adult patients.

Q: What is the main reason Lexopam is prescribed for?

Regulatory product information states that Lexopam is indicated for the short-term symptomatic treatment of severe anxiety. This includes anxiety that is disabling or causing extreme distress. This medication is intended to provide temporary relief from these anxiety manifestations.

Q: Do studies suggest Lexopam is used for long-term or short-term treatment?

Official regulatory documents strongly advise that treatment with Lexopam should be kept as short as possible. The total duration of use, including the necessary dose reduction period, should generally not exceed 8 to 12 weeks. This emphasis reflects the drug's use for short-term relief.

Q: How quickly does Lexopam start working after taking it?

Pharmacokinetic information from official sources suggests that the drug is absorbed fairly rapidly after oral administration. The concentration of the medicine in the blood typically reaches its peak within approximately two hours of taking a dose. This indicates the period when the concentration of the medicine in the blood is highest.

Q: How long does the effect of a Lexopam dose typically last?

Official pharmacokinetic data describes the elimination half-life of the active substance, bromazepam, as being approximately 20 hours. This half-life measurement provides insight into the drug’s clearance rate, but the duration of noticeable clinical effect may vary considerably for each individual.

Q: Is it possible to become dependent on Lexopam?

Yes, official warnings clearly state that the use of benzodiazepines, which includes Lexopam, may lead to physical and psychological dependence. The risk of developing dependence is noted to increase when higher doses are used or when the medication is taken for longer periods of time. For this reason, treatment duration is intended to be short.

Q: What are the most common side effects listed for Lexopam?

Official product information lists several commonly reported side effects. These include feeling drowsy or tired, experiencing dizziness, and some loss of muscle coordination. These effects are often most noticeable at the start of treatment as the body adjusts to the medication.

Q: Can Lexopam cause changes in mood or thinking?

Regulatory warnings describe the potential for changes in mood or thinking, including what are called paradoxical reactions. These are unusual reactions such as restlessness, agitation, aggression, or even delusion. Additionally, official information notes that Lexopam may sometimes worsen existing symptoms of depression in certain patients.

Q: Are there any documented interactions between Lexopam and common over-the-counter pain relievers?

Official drug reports indicate that the metabolism of Lexopam can potentially be affected by certain nonsteroidal anti-inflammatory drugs (NSAIDs) and Acetaminophen. This means these common over-the-counter pain relievers could impact how the body processes the medication.

Q: Is Lexopam safe to take with alcohol, according to official warnings?

Official warnings strongly state that the concurrent use of Lexopam and alcohol is advised against. Alcohol can significantly increase the clinical effects of the medicine, leading to severe sedation, profound sleepiness, and potentially dangerous respiratory depression (slowed breathing).

Q: Why do some people experience initial drowsiness when starting Lexopam?

The initial drowsiness or tiredness is a common side effect described in official product information. Lexopam acts as a central nervous system depressant, which means it slows down activity in the brain. This action is the reason some individuals feel sleepy, especially during the first few days of treatment.

Q: Is Lexopam often used alongside other types of mental health medicines?

Regulatory warnings advise that caution should be exercised when Lexopam is prescribed alongside other medicines that also depress the central nervous system (CNS). This includes certain other types of mental health medicines. Combining CNS depressants can increase the risk of severe sedation and profound respiratory depression.

Q: What kind of research has been done on Lexopam's effectiveness?

The effectiveness of the drug in treating symptoms has been demonstrated in clinical studies. However, official labels emphasize that continuous long-term use is not recommended. This conservative approach is due to limited long-term safety data and the risk of dependence.

Q: Does the official information state Lexopam is safe during pregnancy?

Official documents advise against the use of this medication during pregnancy. Like other medicines in its class, it should only be used if the potential therapeutic benefit is considered to outweigh the potential risks to the developing fetus.

Q: Can Lexopam cause sleep problems or insomnia?

Official product information indicates that insomnia can be a reported side effect of the medicine. Furthermore, there is a recognized potential for rebound insomnia, which is a temporary increase in sleep disturbance or difficulty sleeping, when the medication is abruptly stopped.

Q: Is there a generic version of Lexopam available?

Lexopam is the brand name for the active substance known as bromazepam. Depending on the country and market availability, bromazepam is sold under its chemical name or under various different brand names, which are considered generic versions of the drug.

Q: Does taking Lexopam affect the results of any common lab tests?

Official guidance indicates that, in rare instances, taking this medicine has been associated with an elevation of liver enzymes. Because of this, regular monitoring of blood counts and liver function tests may be indicated during treatment.

Q: Is Lexopam classified as a controlled substance?

Regulatory bodies classify Lexopam (bromazepam) as a Schedule IV controlled substance. This classification, recognized internationally, indicates that the medicine has a recognized medical use but also a low potential for abuse relative to certain substances in higher schedules.

Q: What is the risk of experiencing severe or serious side effects from Lexopam?

Like all medicines, Lexopam carries a risk of serious side effects, although these are generally less common. Regulatory documents list serious reactions such as seizures, severe memory loss (amnesia), and yellowing of the skin or eyes (jaundice). Severe allergic reactions are also possible and require medical review.

Q: Are headaches a commonly reported side effect in clinical trials?

Official product information lists headaches as a possible adverse reaction, or side effect, to the medicine. Headaches are also a symptom that is frequently reported by patients during the period of withdrawal or discontinuation when the dose is being reduced.

Q: Do official documents mention Lexopam's potential for recreational misuse?

Yes, regulatory warnings explicitly highlight the potential for the medicine to be subject to abuse, misuse, and addiction. The risk associated with this potential is recognized to be greater in patients who have a documented history of alcohol or drug abuse.

Q: Why is Lexopam sometimes referred to as an anxiolytic?

Lexopam is referred to as an anxiolytic because it possesses anxiolytic properties. This simply means that the drug is able to diminish feelings of anxiety and tension, which is its primary therapeutic effect. This action is achieved through its positive modulation of certain inhibitory receptors in the central nervous system.

Q: Are there any known food items that interact with Lexopam?

Official information states that the influence of food on the absorption of the medicine is unknown. Because of this uncertainty, the tablets are generally advised to be taken on an empty stomach. Specific food items that cause problematic interactions are generally not detailed in the product label.

Q: Can Lexopam cause changes in appetite?

Changes in appetite are not listed as a common direct side effect in all regulatory documents. However, official information on associated conditions, such as depression, sometimes includes signs like changes in weight or appetite.

Q: What should a patient know about operating machinery while taking Lexopam?

Official warnings state that patients should be cautioned against operating dangerous machinery or driving motor vehicles. This is because the medicine can cause sedation, dizziness, and impaired muscular function.

Q: Do official sources list withdrawal symptoms associated with stopping Lexopam?

Yes, official product information lists a range of withdrawal symptoms that may occur if the medicine is discontinued abruptly. These symptoms can include headaches, muscle pain, tension, and restlessness. More severe symptoms, such as confusion or epileptic seizures, are possible.

Q: How long does it take for Lexopam to be completely out of the body?

Based on pharmacokinetic data, the drug’s half-life is approximately 20 hours. Generally, it takes about five times the half-life for a medication to be almost completely eliminated from the body. Therefore, the active substance is estimated to be largely out of the system within 2 to 3 days after the final dose.

Q: Can Lexopam worsen symptoms of depression?

Regulatory warnings advise that Lexopam, similar to other medicines in its class, may increase symptoms of depression in some patients. Due to this potential effect, the medication is not recommended as the sole or primary treatment for individuals diagnosed with depression.

Q: Are there warnings about Lexopam for people with breathing problems?

Yes, official warnings emphasize that the medicine can suppress a person’s breathing. For this reason, Lexopam is contraindicated, meaning it should not be used, in patients who have severe respiratory insufficiency or a condition like sleep apnea.

Q: What does the FDA label say about Lexopam for panic disorder?

While Lexopam is not explicitly approved by the U.S. FDA, international regulatory documents list the medicine for the short-term treatment of anxiety. This therapeutic use includes the relief of anxiety associated with panic states.

Q: Are allergic reactions to Lexopam rare?

Severe allergic reactions are generally considered rare events, but they are listed in regulatory documents as a serious potential side effect.

Q: Is Lexopam linked to memory issues?

Yes, official warnings state that transient amnesia, or temporary memory impairment, has been reported with the use of this medication. Regulatory information indicates that the risk of experiencing memory issues generally increases when higher dosages are prescribed.

Q: How does the drug's purpose relate to anxiety disorders in general?

The medicine's primary purpose is the symptomatic relief of excessive anxiety. This is achieved through its mechanism of action, which gives it anxiolytic (anxiety-reducing) properties. It works by modulating specific receptors in the central nervous system to decrease neural excitability.

Q: Is it typical for Lexopam treatment to involve regular monitoring by a healthcare provider?

Official guidelines recommend that all patients receiving treatment with Lexopam should be reassessed by a healthcare provider on a regular basis. This monitoring is necessary to evaluate the patient's condition and determine the ongoing need for continued treatment.

Q: What are the risks of taking Lexopam during the first trimester of pregnancy?

Taking Lexopam during the first trimester of pregnancy is advised against unless absolutely necessary due to potential risks. Regulatory information associated with this class of medication suggests an increased risk of miscarriage during the earliest stages of pregnancy.

Q: Can Lexopam be taken by someone with kidney problems?

Official guidance advises that patients with impaired renal (kidney) function should use the medication with caution. In these cases, a dosage reduction may be advisable to prevent the accumulation of the medicine in the body.

Q: Are there specific conditions that require extra caution when prescribing Lexopam?

Yes, regulatory documents list several conditions that require extra caution when prescribing this medicine. These include acute narrow angle glaucoma, individuals with a history of drug or alcohol abuse, and patients for whom a drop in blood pressure (hypotension) could lead to serious cardiac or cerebral complications.

How should Lexopam be stored and disposed of?

How to Store and Dispose of Lexopam?

Lexopam (Bromazepam) tablets must be stored and disposed of according to official regulatory guidelines to maintain stability and prevent misuse, as the medication is classified as a controlled substance.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 68^circF to 77^circF (20^circC to 25^circC).
Environment Keep in a dry place; avoid excess heat, moisture, and do not store in the bathroom.
Packaging Keep in its original, tightly closed container.
Child Safety Must be kept out of the reach of children and stored in a safe, locked area to prevent accidental ingestion.

Disposal

Do not dispose of the tablets in wastewater (e.g., toilet or sink) or household trash. The preferred method is to use an official drug take-back program. Consult a pharmacist or local health authority for approved disposal methods for unused or expired controlled substances.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lexopam found in:

A-Z Index: